Networks in Neurology: New Agents and Strategies for Migraine

Activity Description 

One out of six US adults suffer from migraines and yet, until recently, management has been reliant on treatments designed for other conditions that had some consequential success. Fortunately, this long-standing paradigm has not only ended but has accelerated in the opposite direction. The rapid acquisition of new therapies has created a near impossible amount of information to parse out efficiently. This curriculum, originally presented as a small group interactive learning program through RealCME’s Gather-Ed platform, is designed to help participants improve their migraine management skills by distilling what information is most relevant in the evolving world and what it means for patients. The activity features an in-depth interview with a renowned headache specialist, Dr Shivang Joshi, regarding the appropriate application of recent advances in headache medicine. Throughout the activity, Dr Joshi reviews his own management approaches for a variety of scenarios relevant to modern practice as well as those of the other experts involved in this project.

Target Audience

This activity is intended for neurologists involved in the care of patients with migraine and other headache disorders.

Learning Objectives

  1. Compare and contrast your management approaches for patients with diverse presentations of migraine to physicians that specialize in the care of the disease and affirm or modify your planned decision-making accordingly.
  2. Recognize the indications for the use of preventive treatment in patients suffering from episodic and chronic migraine to ensure its timely consideration by these individuals.
  3. Review the therapeutic profiles associated with FDA-approved calcitonin gene-related peptide (CGRP) monoclonal antibodies for the prevention of episodic and chronic migraine and discern how and for whom these agents can be appropriately prescribed.
  4. Describe the mechanisms of action and clinical profiles of recently approved abortive medications for the management of migraine and identify individuals that may be candidates for these therapies.
Course summary
Available credit: 
  • 1.25 AMA PRA Category 1 Credit™
Course opens: 
03/08/2021
Course expires: 
03/08/2022
Cost:
$0.00
Rating: 
0

Faculty

   Shivang Joshi, MD, MPH, RPh​ (Chair)
   Associate Professor of Clinical Pharmacy Practice 
   University of Buffalo School of Pharmacy  ​
   Neurologist/Headache Specialist​
   DENT Neurological Institute​
   Amherst, New York
 

   Ryan Smith, DO​ (Moderator)
   Assistant Professor of Neurology​
   Idaho College of Osteopathic Medicine​
   Clinical Instructor​
   University of Washington​
   Director of Headache Medicine​
   St Luke's Health System ​
   Boise, Idaho

 

Surveyed Experts

  Jessica Ailani, MD​
  Professor of Neurology​
  Georgetown University Hospital​
  Director​
  MedStar Georgetown
  Headache Center​
  Washington, DC​
  

   Wade Cooper, DO​

   Clinical Associate Professor ​of Neurology​
   Clinical Associate Professor ​in Anesthesiology​
   Director, Headache & Neuropathic Pain ​
   University of Michigan School of Medicine​
   Ann Arbor, Michigan

 

  Ira Turner, MD​
  Chief​
  The Center for Headache Care and Research
  at​ Island Neurological Associates, P.C.​
  Plainview, New York​

This activity is jointly provided by Postgraduate Institute for Medicine and Efficient LLC. 

 

Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Efficient LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education(ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Designation Statement
PIM designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Conflict of Interest Disclosure Policy

Disclosures

PIM requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners' and Managers' Disclosure

PIM planners and managers have nothing to disclose. Efficient LLC planners and managers have nothing to disclose.

Faculty Disclosures

Dr Ailani reports the following financial relationships:
  • Consulting fees: Allergan/Abbvie, Axsome Therapeutics, Biohaven Pharmaceuticals Inc., Lilly, Lundbeck, Satsuma Pharmaceuticals Inc., Teva Pharmaceuticals, Theranica
  • Contracted research: Allergan/Abbvie, Biohaven Pharmaceuticals Inc., Satsuma Pharmaceuticals Inc., Zosano Pharma
  • Fees for Non-CME/CE Services: Allergan/Abbvie, Biohaven Pharmaceuticals Inc., Lilly, Lundbeck, Teva Pharmaceuticals
  • Stock options: Ctrl M Health
Dr Cooper reports the following financial relationships
  • Consulting fees: Amgen, Dolor Technologies, Lilly, Lundbeck, Teva Pharmaceuticals, Theranica
  • Ownership interest: Dolor Technologies
Dr Joshi reports the following financial relationships:
  • Consulting fees: Allergan, Amgen, Biohaven Pharmaceuticals Inc., Lilly, Teva Pharmaceuticals
Dr Smith reports the following financial relationships:
  • Consulting fees: Allergan
  • Fees for Non-CME/CE Services: Allergan, Amgen, Lilly, Teva
Dr Turner reports the following financial relationships:
  • Consulting fees: Allergan, Amgen, Biohaven Pharmaceuticals Inc., Lilly, Lundbeck, Novartis Pharmaceuticals Corp., Revance Therapeutics Inc., Teva Pharmaceuticals, Theranica
  • Contracted research: Allergan, Lilly, Teva Pharmaceuticals, Theranica

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Commercial Support

This activity is supported by educational grants from Lilly and Teva Pharmaceuticals

Available Credit

  • 1.25 AMA PRA Category 1 Credit™

Price

Cost:
$0.00
Please login or register to take this course.